Noticias y Actividades de Affini-T Therapeutics
Ejecutivos
Ver el organigrama con sus 9 ejecutivos principales
Biografías más buscadas en Affini-T Therapeutics
- Jak Knowles, Co-Founder, President, Chief Executive Officer and Di...
- Helen Kim, Director
- Jill Desimone, Director
Recientes movimientos de ejecutivos en Affini-T Therapeutics
- Loïc Vincent, Chief Scientific Officer, ha dejado la empresa (noticia publicada el 2 de abril de 2025).
- Loïc Vincent, Chief Scientific Officer, ha dejado la empresa (noticia publicada el 2 de abril de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en Affini-T Therapeutics.
Biotecnología
Affini-T Therapeutics tiene 2.339 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Biogen (Estados Unidos).
Popular M&A news in Biotecnología
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (publicado el 30 de abril de 2025)..
- Deepull acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 29 de abril de 2025).
- Biolinq acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 23 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Affini-T Therapeutics
- Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics to Present Data from Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Affini-T Therapeutics
- Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- View more press releases Close
Redes sociales sobre Affini-T Therapeutics
- Affini-T Therapeutics en Wikipedia, Google News y Yahoo Finance
- Affini-T Therapeutics en LinkedIn, Twitter y YouTube
